Raffi F, et al. Switching from an abacavir (ABC)/lamivudine (3TC)-based regimen to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF): Cardiovascular disease risk profile analysis from a randomized controlled study in virologically-suppressed adults. AIDS 2018.
5-alfa-reductaseremmers geassocieerd met minder COVID-19-symptomen bij mannen met alopecia androgenetica
feb 2021 | Virale infecties